---
layout: default
title: Activated Charcoal Apis Mellifera Artemisia Cina P
parent: 僅模型預測 (L5)
nav_order: 193
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Apis Mellifera Artemisia Cina P
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-ingredient Homeopathic Combination: Insufficient Data for TxGNN Evaluation

## One-Sentence Summary

This candidate is a 15-ingredient homeopathic combination product — including activated charcoal, bee venom (*Apis mellifera*), and botanical/mineral extracts — that is not currently marketed in Taiwan and carries no approved indication on record.
The TxGNN model was **unable to generate any repurposing predictions** for this compound, most likely because none of its ingredients could be matched to a DrugBank node in the knowledge graph.
Without a mapped drug identity or a predicted target disease, a standard drug repurposing evaluation cannot be completed at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Drug Identifier | 15-ingredient combination (no single INN, no DrugBank ID) |
| Original Indication | None on record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only) — effectively **below L5**: no prediction was generated |
| Taiwan Market Status | Not marketed |
| Number of Licenses | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

The TxGNN knowledge graph maps each candidate drug to a DrugBank node, then traverses disease-association edges to score novel indications. This pipeline requires at minimum one resolvable DrugBank ID.

This candidate presents three compounding obstacles:

1. **No DrugBank ID available.** The `drugbank_id` field is null, and the query log confirms that even though the DrugBank source returned a result count of 1, no ID was recorded — suggesting the match was ambiguous or returned a partial/unlinked record.

2. **Homeopathic and botanical ingredients.** Most of the 15 components (*Apis mellifera*, *Pulsatilla montana*, *Sepia officinalis*, *Veratrum album*, etc.) are homeopathic or crude botanical preparations that are either absent from the DrugBank small-molecule database or appear only as nutraceutical entries without pharmacological targets.

3. **Multi-ingredient complexity.** The combination has no unified mechanism of action. Each ingredient would require independent mapping, and combination-level synergy predictions are outside TxGNN's current model scope.

Until a reliable DrugBank anchor is established for at least the pharmacologically active ingredients (e.g., activated charcoal, potassium alum), the knowledge graph cannot propagate a prediction score.

---

## Taiwan Market Information

This drug has **zero active licenses** in Taiwan and is not marketed. No authorization table can be generated.

---

## Safety Considerations

Please refer to the package insert for safety information.

> Note: Individual ingredients carry distinct safety profiles. Activated charcoal can adsorb co-administered medications; *Veratrum album* contains veratrum alkaloids with narrow therapeutic indices; *Delphinium staphisagria* contains delphinine, a cardiotoxic alkaloid. Any future clinical evaluation should treat these ingredients separately rather than as a unified safety entity.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
TxGNN produced no repurposing candidates because the drug cannot be resolved to a knowledge graph node, and no original indication or existing evidence base exists to support a manual hypothesis either.

**To proceed, the following is needed:**

- **Resolve DrugBank identity** — manually verify which (if any) of the 15 ingredients maps to an active DrugBank small-molecule entry; activated charcoal (`DB01882`) and sodium chloride (`DB09154`) are directly identifiable and could serve as anchors for a narrowed query.
- **Clarify intended therapeutic indication** — determine the clinical context in which this combination was formulated; without this, neither a repurposing hypothesis nor a comparator trial can be identified.
- **Evaluate ingredient-by-ingredient** — run TxGNN predictions for pharmacologically tractable individual components (e.g., activated charcoal for gastrointestinal or toxicological indications) rather than the mixture as a whole.
- **Assess regulatory pathway** — as a homeopathic combination not registered in Taiwan, any development path would require engagement with TFDA's special review track for traditional/complementary medicines before standard NDA repurposing analysis applies.
- **Safety dossier for active botanicals** — commission a full toxicology review for *Veratrum album* root and *Delphinium staphisagria* seed before any human study is considered.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

